ani pharmaceuticals is an integrated specialty pharmaceutical company focused on delivering value to our customers by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceuticals. we focus on niche and high barrier to entry opportunities including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. our two pharmaceutical manufacturing facilities located in baudette, minnesota are capable of producing oral solid dose products, as well as liquids and topicals, controlled substances, and potent products that must be manufactured in a fully-contained environment. our objective is to create long term shareholder value by building a sustainable and growing base business in generic and mature brand pharmaceutical products while advancing an opportunity to re-commercialize cortrophin gel and cortrophin-zinc.
Company profile
Ticker
ANIP
Exchange
Website
CEO
Patrick Walsh
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
BEN ABRAHAM TECHNOLOGIES INC, BIOSANTE PHARMACEUTICALS INC
SEC CIK
Corporate docs
Subsidiaries
ANIP Acquisition Company • ANI Pharmaceuticals Canada Inc. • Novitium Pharma, LLC • New Castle Pharma LLC • Novitium Labs Private Limited • New Castle Pharma Real Estate LLC • ANI Rare Disease Patient Assistance Program, Inc. ...
IRS number
582301143
ANIP stock data
Latest filings (excl ownership)
8-K
Results of Operations and Financial Condition
17 Apr 24
ARS
2023 FY
Annual report to shareholders
5 Apr 24
DEFA14A
Additional proxy soliciting materials
5 Apr 24
DEF 14A
Definitive proxy
5 Apr 24
8-K
Results of Operations and Financial Condition
12 Mar 24
10-K
2023 FY
Annual report
29 Feb 24
8-K
ANI Pharmaceuticals Reports Fourth Quarter and Record Full-Year 2023 Financial Results and Provides 2024 Guidance
29 Feb 24
8-K
Entry into a Material Definitive Agreement
23 Feb 24
8-K
Results of Operations and Financial Condition
8 Feb 24
8-K
Results of Operations and Financial Condition
8 Jan 24
Transcripts
ANIP
Earnings call transcript
2023 Q3
8 Nov 23
ANIP
Earnings call transcript
2023 Q2
9 Aug 23
ANIP
Earnings call transcript
2023 Q1
8 May 23
ANIP
Earnings call transcript
2022 Q4
9 Mar 23
ANIP
Earnings call transcript
2022 Q3
9 Nov 22
ANIP
Earnings call transcript
2022 Q2
8 Aug 22
ANIP
Earnings call transcript
2022 Q1
10 May 22
ANIP
Earnings call transcript
2021 Q4
15 Mar 22
ANIP
Earnings call transcript
2021 Q3
1 Nov 21
ANIP
Earnings call transcript
2021 Q2
6 Aug 21
Latest ownership filings
144
Notice of proposed sale of securities
18 Apr 24
4
Muthusamy Shanmugam
17 Apr 24
144
Notice of proposed sale of securities
17 Apr 24
144
Notice of proposed sale of securities
16 Apr 24
144
Notice of proposed sale of securities
15 Apr 24
4
Meredith Cook
15 Apr 24
4
James G. Marken
11 Apr 24
4
STEPHEN P. CAREY
11 Apr 24
3
Thomas Andrew Rowland
8 Apr 24
4
Chad Gassert
2 Apr 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q4 2023
48.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 130 |
Opened positions | 18 |
Closed positions | 75 |
Increased positions | 34 |
Reduced positions | 45 |
13F shares | Current |
---|---|
Total value | 313.29 bn |
Total shares | 10.12 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Meridian Venture Partners II GP | 1.64 mm | $86.99 mm |
Rubric Capital Management | 1.13 mm | $0.00 |
Esjay | 932.62 k | $48.92 mm |
Deep Track Capital | 600.00 k | $33.08 bn |
STT State Street | 592.42 k | $32.67 bn |
Dimensional Fund Advisors | 591.73 k | $32.63 bn |
Global Alpha Capital Management | 582.43 k | $32.12 bn |
William Blair Investment Management | 490.56 k | $27.05 bn |
IVZ Invesco | 258.45 k | $14.25 bn |
MS Morgan Stanley | 231.94 k | $12.79 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
17 Apr 24 | Muthusamy Shanmugam | Common Stock | Sell | Dispose S | Yes | Yes | 65.4 | 9,520 | 622.61 k | 809,852 |
16 Apr 24 | Muthusamy Shanmugam | Common Stock | Sell | Dispose S | Yes | Yes | 66.2 | 5,834 | 386.21 k | 819,372 |
15 Apr 24 | Muthusamy Shanmugam | Common Stock | Sell | Dispose S | Yes | Yes | 66.33 | 7,414 | 491.77 k | 825,206 |
12 Apr 24 | Meredith Cook | Common Stock | Sell | Dispose S | No | Yes | 67.79 | 250 | 16.95 k | 59,731 |
10 Apr 24 | Marken James G. | Common Stock | Payment of exercise | Dispose F | No | No | 66.96 | 2,799 | 187.42 k | 116,006 |
10 Apr 24 | Carey Stephen P. | Common Stock | Payment of exercise | Dispose F | No | No | 66.96 | 4,534 | 303.60 k | 166,968 |
1 Apr 24 | Chad Gassert | Common Stock | Sell | Dispose S | Yes | Yes | 67.25 | 20,000 | 1.35 mm | 253,226 |
News
Moderna (MRNA) Up 6% on Upbeat Data From Cancer Jab Study
11 Apr 24
ANI Pharmaceuticals Announces The Launch Of Baclofen Oral Suspension
9 Apr 24
ANI Pharmaceuticals Announces the Launch of Levofloxacin Oral Solution, USP
27 Mar 24
Capital One Initiates Coverage On ANI Pharmaceuticals with Overweight Rating
15 Mar 24
Alphabet, Dover And 2 Other Stocks Insiders Are Selling
11 Mar 24
Press releases
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)
11 Apr 24
ANI Pharmaceuticals Announces the Launch of Baclofen Oral Suspension
9 Apr 24
ANI Pharmaceuticals Recognizes Sarcoidosis Awareness Month and Patients Living with Sarcoidosis
4 Apr 24
ANI Pharmaceuticals to Participate at the Piper Sandler Spring Biopharma Symposium
3 Apr 24
ANI Pharmaceuticals Announces the Launch of Levofloxacin Oral Solution, USP
27 Mar 24